Hints and tips:
Related Special Reports
...“All it takes is one large company like Eli Lilly to do it and then more risk-averse companies follow suit,” he said....
...Other drugmakers could still “win” the race in the rapidly growing obesity market dominated by Novo Nordisk and Eli Lilly, according to the chief executive of biotech company Zealand Pharma....
...Eli Lilly and Vertex declined to comment on the talks....
...Eli Lilly has made cuts in Europe and reduced the number of clinical trials there, he added. But some campaigners for access to medicines welcomed the proposals....
...Eli Lilly’s chief executive David Ricks attributed the drugmaker’s performance to “strong sales of Mounjaro and Zepbound”, and said the company was “rapidly expanding manufacturing capacity to make our incretin...
...Eli Lilly’s weight-loss drug tirzepatide significantly reduced sleep apnoea problems in a late-stage clinical trial, the pharmaceutical group said on Wednesday, adding to evidence that could encourage more...
...The addition of Amazon Pharmacy to Eli Lilly’s direct-to-consumer dispensing network is the first time Amazon has partnered with a big drug company since it launched its online pharmacy business in 2020....
...Dear reader, It isn’t often that a company pays good money to criticise customers for buying its product. But that is what Eli Lilly did this week....
...Developed respectively by Novo Nordisk and Eli Lilly, they are now being prescribed to millions of people....
...BSP previously produced Covid antibody treatment bamlanivimab for Eli Lilly....
...Patients on the donanemab study had more advanced Alzheimer’s than patients on similar studies, Eli Lilly said....
...Demand for a new class of diabetes and obesity drugs will boost US drugmaker Eli Lilly’s sales by 20 per cent in 2024, pushing its revenues above $40bn, the company said on Tuesday....
...High demand for weight-loss drugs has helped Novo Nordisk become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s largest pharmaceutical company...
...The retail giant struck a deal earlier this month to dispense medication on behalf of Zepbound maker Eli Lilly’s direct-to-consumer service LillyDirect....
...Eli Lilly has called for competition regulators to scrutinise an $11bn deal by its main competitor Novo Nordisk to snap up additional manufacturing capacity, as the rivalry between the drugmakers to dominate...
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
...Mounjaro will become available “within weeks” in Great Britain for treatment of both diabetes and obesity, after the medicines regulator authorised US pharma company Eli Lilly on Thursday to sell the weight...
...Eli Lilly lowered its expectations for full-year earnings because of accounting charges related to recent acquisitions, despite beating expectations in the third quarter driven by growth in diabetes and...
...The side effects of Eli Lilly’s and Novo Nordisk’s obesity treatments are very similar, and patients could switch from one to the other, Stanford said....
...Indianapolis-based Eli Lilly, meanwhile, has become the world’s largest pharmaceutical company on the back of sales of its drug Mounjaro for diabetes and strong trial results for its use in weight loss....
...This is a very small deal for a company as big as Eli Lilly. The drugs giant is riding high on diabetes drug Mounjaro, which has potential use as a weight-loss treatment....
...The US federal drug regulator has approved Eli Lilly’s injectable diabetes medication for weight loss, as demand for the blockbuster treatments continues to surge....
...Eli Lilly, the world’s largest drugmaker, plans to bolster its portfolio of cancer drugs by buying Point Biopharma for $1.4bn, paying a premium of almost 90 per cent to Monday’s closing price....
...Hassabis stated the goal days after announcing Isomorphic Lab’s first two pharmaceutical partnerships with Eli Lilly and Novartis, which came to a combined value of up to $3bn, in deals set to transform...
International Edition